The therapeutic potential of cannabidiol (CBD), a non-psychtropic component of the Cannabis sativa plant, is substantiated more and more. We aimed to determine the pharmacokinetic behavior of CBD after a single dose via intranasal (IN) and intrarectal (IR) administration in six healthy Beagle dogs age 3-8 years old, and compare to the oral administration route (PO). Standardized dosages applied for IN, IR and PO were 20, 100, and 100 mg, respectively. Each dog underwent the same protocol but received CBD through a different administration route. CBD plasma concentrations were determined by ultra-high performance liquid chromatography-tandem mass spectrometry before and at fixed time points after administration. Non-compartmental analysis was performed on the plasma concentration-time profiles. Plasma CBD concentrations after IR administration were below the limit of quantification. The mean area under the curve (AUC) after IN and PO CBD administration was 61 and 1,376 ng/mL*h, respectively. The maximal plasma CBD concentration (Cmax) after IN and PO CBD administration was 28 and 217 ng/mL reached after 0.5 and 3.5 h (Tmax), respectively. Significant differences between IN and PO administration were found in the Tmax (p = 0.04). Higher AUC and Cmax were achieved with 100 mg PO compared to 20 mg IN, but no significant differences were found when AUC (p = 0.09) and Cmax (p = 0.44) were normalized to 1 mg dosages. IN administration of CBD resulted in faster absorption when compared to PO administration. However, PO remains the most favorable route for CBD delivery due to its more feasible administration. The IR administration route is not advised for clinical application.

CBDepot Teplice Czechia

Centre for Clinical Veterinary Medicine Ludwig Maximilian University of Munich Munich Germany

Clinic for Small Animals Department of Neurology University of Veterinary Medicine Hannover Hannover Germany

Department of Clinical Sciences Faculty of Veterinary Medicine Utrecht University Utrecht Netherlands

Department of Pathobiology Pharmacology and Zoological Medicine Faculty of Veterinary Medicine Ghent University Ghent Belgium

Laboratory of Animal Genetics Faculty of Veterinary Medicine Ghent University Ghent Belgium

Small Animal Department Small Animal Teaching Hospital Faculty of Veterinary Medicine Ghent University Ghent Belgium

Zobrazit více v PubMed

Carlini EA, Cunha JM. Hypnotic and antiepileptic effects of cannabidiol. J Clin Pharmacol. (1981) 21:417–27. 10.1002/j.1552-4604.1981.tb02622.x PubMed DOI

Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernández- Ruiz J. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity PubMed DOI

Blessing EM, Steenkamp MM, Manzanares J, Marmar CR. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics. (2015) 12:825–36. 10.1007/s13311-015-0387-1 PubMed DOI PMC

Reddy DS. The utility of cannabidiol in the treatment of refractory epilepsy. Clin Pharmacol Ther. (2017) 101:182–4. 10.1002/cpt.441 PubMed DOI

Pisanti S, Malfitano AM, Ciaglia E, Lamberti A, Ranieri R, Cuomo G, et al. Cannabidiol: state of the art and new challenges for therapeutic applications. Pharm Ther. (2017) 175:133–50. 10.1016/j.pharmthera.2017.02.041 PubMed DOI

Gamble LJ, Boesch JM, Frye CW, Schwark WS, Mann S, Wolfe L, et al. Pharmacokinetics, safety, and clinical efficacy of cannabidiol treatment in osteoarthritic dogs. Front Vet Sci. (2018) 5:165. 10.3389/fvets.2018.00165 PubMed DOI PMC

McGrath S, Bartner LR, Rao S, Packer R, Gustafson DL. Randomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional anti-epileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy. J Am Vet Med Assoc. (2019) 254:1301–8. 10.2460/javma.254.11.1301 PubMed DOI

Mechoulam R, Shvo Y, Hashish I. The structure of cannabidiol. Tetrahedron. (1963) 19:2073–8. 10.1016/0040-4020(63)85022-X PubMed DOI

Mechoulam R, Shani A, Edery H, Grunfeld Y. Chemical basis of hashish activity. Science. (1970) 169:611–12. 10.1126/science.169.3945.611 PubMed DOI

Turner CE, ElSohly MA, Boeren EG. Constituents of PubMed DOI

Russo EB. Cannabis and epilepsy: an ancient treatment returns to the fore. Epilepsy Behav. (2017) 70:292–7. 10.1016/j.yebeh.2016.09.040 PubMed DOI

Pellesi L, Licata M, Verri P, Vandelli D, Palazzoli F, Marchesi F, et al. Pharmacokinetics and tolerability of oral cannabis preparations in patients with medication overuse headache (MOH)-a pilot study. Eur J Clin Pharmacol. (2018) 74:1427–36. 10.1007/s00228-018-2516-3 PubMed DOI

Brodie MJ, Ben-Menachem E. Cannabinoids for epilepsy: what do we know and where do we go? Epilepsia. (2018) 59:291–6. 10.1111/epi.13973 PubMed DOI

dos Santos RG, Hallak JE, Leite JP, Zuardi AW, Crippa JAS. Phytocannabinoids and epilepsy. J Clin Pharm Ther. (2015) 40:135–43. 10.1111/jcpt.12235 PubMed DOI

Freundt-Revilla J, Kegler K, Baumgärtner W, Tipold A. Spatial distribution of cannabinoid receptor type 1 (CB1) in normal canine central and peripheral nervous system. PLoS ONE. (2017) 12:e0181064. 10.1371/journal.pone.0181064 PubMed DOI PMC

Freundt-Revilla J, Heinrich F, Zoerner A, Gesell F, Beyerbach M, Shamir M, et al. The endocannabinoid system in canine steroid-responsive meningitis-arteritis and intraspinal spirocercosis. PLoS ONE. (2018) 13:e0187197. 10.1371/journal.pone.0187197 PubMed DOI PMC

El-Remessy AB, Al-Shabrawey M, Khalifa Y, Tsai NT, Caldwell RB, Liou GI. Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. Am J Pathol. (2006) 168:235–44. 10.2353/ajpath.2006.050500 PubMed DOI PMC

Carrier EJ, Auchampach JA, Hillard CJ. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci USA. (2006) 103:7895–900. 10.1073/pnas.0511232103 PubMed DOI PMC

Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia. (2014) 55:791–802. 10.1111/epi.12631 PubMed DOI PMC

Leo A, Russo E, Elia M. Cannabidiol and epilepsy: rationale and therapeutic potential. Pharmacol Res. (2016) 107:85–92. 10.1016/j.phrs.2016.03.005 PubMed DOI

Golub V, Reddy DS. Cannabidiol therapy for refractory epilepsy and seizure disorders. Adv Exp Med Biol. (2021) 1264:93–110. 10.1007/978-3-030-57369-0_7 PubMed DOI

Esposito G, Scuderi C, Savani L, Steardo D, Jr, De Filippis P, Cottone T, et al. Cannabidiol PubMed DOI PMC

Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. (2005) 65:812–9. 10.1212/01.wnl.0000176753.45410.8b PubMed DOI

Pertwee RG. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol. (2009) 156:397–411. 10.1111/j.1476-5381.2008.00048.x PubMed DOI PMC

Verrico CD, Wesson S, Konduri V, Hofferek CJ, Vazquez-Perez J, Blair E, et al. A randomized, double-blind, placebo-controlled study of daily cannabidiol for the treatment of canine osteoarthritis pain. Pain. (2020) 161:2191–202. 10.1097/j.pain.0000000000001896 PubMed DOI PMC

Mejia S, Duerr FM, Griffenhagen G, McGrath S. Evaluation of the effect of cannabidiol on naturally occurring osteoarthritis-associated pain: a pilot study in dogs. J Am Anim Hosp Assoc. (2021) 57:81–90. 10.5326/JAAHA-MS-7119 PubMed DOI

Corsetti S, Borruso S, Malandrucco L, Spallucci V, Maragliano L, Perino R, et al. PubMed DOI PMC

Morrow L, Belshaw Z. Does the addition of cannabidiol to conventional antiepileptic drug treatment reduce seizure frequency in dogs with epilepsy? Vet Rec. (2020) 186:492–3. 10.1136/vr.m1593 PubMed DOI

Agurell S, Carlsson S, Lindgren JE, Ohlsson A, Gillespie H, Hollister L. Interactions of delta 1-tetrahydrocannabinol with cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass fragmentography. Experientia. (1981) 37:1090–2. 10.1007/BF02085029 PubMed DOI

Deiana S, Watanabe A, Yamasaki Y, Amada N, Arthur M, Fleming S, et al. Plasma and brain pharmacokinetic profile of Cannabidiol (CBD), cannabidivarine (CBDV), Delta (9)- tetrahydrocannabivarin (D9-THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive compulsive behaviour. Psychopharmacology. (2012) 219:859–73. 10.1007/s00213-011-2415-0 PubMed DOI

Samara E, Bialer M, Mechoulam R. Pharmacokinetics of cannabidiol in dogs. Drug Metab Dispos. (1988) 16:469–72. PubMed

Rotolo MC, Graziano S, Pellegrini M, Corlazzoli D, Antinori L, Porcarelli L, et al. Simple and fast gas-chromatography mass spectrometry assay to assess delta 9-tetrahydrocannabinol and cannabidiol in dogs treated with medical cannabis for canine epilepsy. Curr Pharm Biotechnol. (2017) 18:821–7. 10.2174/1389201018666171122115815 PubMed DOI

European, Commission,. 2002/657/EC: Commission Decision of 12 August 2002 Implementing Council Directive 96/23/EC Concerning the Performance of Analytical Methods and the Interpretation of Results (Text with EEA Relevance) (Notified under Document Number C(2002) 3044)–Publica . Available online at: https://op.europa.eu/en/publication-detail/-/publication/ed928116-a955-4a84-b10a-cf7a82bad858/language-en (accessed May 16, 2022).

European Medicines Agency,. Guideline on Bioanalytical Method Validation . Amsterdam: European Medicines Agency; (2011). Available online at: www.ema.europa.eu/documents/annual-report/annual-report-european-medicines-agency-2011_en.pdf (accessed May 16, 2022).

VICH, GL49 . Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals: Validation of Analytical Methods Used in Residue Depletion Studies|European Medicines Agency. Available online at: www.ema.europa.eu/en/vich-gl49-studies-evaluate-metabolism-residue-kinetics-veterinary-drugs-food-producing-animals (accessed May 16, 2022).

Jogani V, Jinturkar K, Vyas T, Misra A. Recent patents review on intranasal administration for CNS drug delivery. Recent Pat Drug Deliv Formul. (2008) 2:25–40. 10.2174/187221108783331429 PubMed DOI

Kumar NN, Gautam M, Lochhead JJ, Wolak DJ, Ithapu V, Singh V, et al. Relative vascular permeability and vascularity across different regions of the rat nasal mucosa: implications for nasal physiology and drug delivery. Sci Rep. (2016) 6:31732. 10.1038/srep31732 PubMed DOI PMC

Charalambous M, Bhatti SFM, Van Ham L, Platt S, Jeffery ND, Tipold A, et al. Intranasal midazolam versus rectal diazepam for the management of canine status epilepticus: a multicenter randomized parallel-group clinical trial. J Vet Intern Med. (2017) 31:1149–58. 10.1111/jvim.14734 PubMed DOI PMC

Vlerick L, Devreese M, Peremans K, Dockx R, Croubels S, Duchateau L, et al. Pharmacokinetics, absolute bioavailability and tolerability of ketamine after intranasal administration to dexmedetomidine sedated dogs. PLoS ONE. (2020) 15:e0227762. 10.1371/journal.pone.0227762 PubMed DOI PMC

Charalambous M, Volk HA, Van Ham L, Bhatti SFM. First-line management of canine status epilepticus at home and in hospital-opportunities and limitations of the various administration routes of benzodiazepines. BMC Vet Res. (2021) 17:103. 10.1186/s12917-021-02805-0 PubMed DOI PMC

Millar SA, Maguire RF, Yates AS, O'Sullivan SE. Towards better delivery of cannabidiol (CBD). Pharmaceuticals. (2020) 13:219. 10.3390/ph13090219 PubMed DOI PMC

Itin C, Barasch D, Domb AJ, Hoffman A. Prolonged oral transmucosal delivery of highly lipophilic drug cannabidiol. Int J Pharm. (2020) 581:119276. 10.1016/j.ijpharm.2020.119276 PubMed DOI

Itin C, Domb AJ, Hoffman A. A meta-opinion: cannabinoids delivered to oral mucosa by a spray for systemic absorption are rather ingested into gastro-intestinal tract: the influences of fed / fasting states. Expert Opin Drug Deliv. (2019) 16:1031–5. 10.1080/17425247.2019.1653852 PubMed DOI

Musulin SE, Mariani CL, Papich MG. Diazepam pharmacokinetics after nasal drop and atomized nasal administration in dogs. J Vet Pharmacol Ther. (2011) 34:17–24. 10.1111/j.1365-2885.2010.01186.x PubMed DOI

Paudel KS, Hammell DC, Agu RU, Valiveti S, Stinchcomb AL. Cannabidiol bioavailability after nasal and transdermal application: effect of permeation enhancers. Drug Dev Ind Pharm. (2010) 36:1088–97. 10.3109/03639041003657295 PubMed DOI

Odi R, Bibi D, Wager T, Bialer M. A perspective on the physicochemical and biopharmaceutic properties of marketed antiseizure drugs-From phenobarbital to cenobamate and beyond. Epilepsia. (2020) 61:1543–52. 10.1111/epi.16597 PubMed DOI

Tapley P, Kellett S. Cannabis-based medicines and the perioperative physician. Perioper Med. (2019) 8:19. 10.1186/s13741-019-0127-x PubMed DOI PMC

Bruni N, Della Pepa C, Oliaro-Bosso S, Pessione E, Gastaldi D, Dosio F. Cannabinoid delivery systems for pain and inflammation treatment. Molecules. (2018) 23:2478. 10.3390/molecules23102478 PubMed DOI PMC

Vaughn DM, Paulionis LJ, Kulpa JE. Randomized, placebo-controlled, 28-day safety and pharmacokinetics evaluation of repeated oral cannabidiol administration in healthy dogs. Am J Vet Res. (2021) 82:405–16. 10.2460/ajvr.82.5.405 PubMed DOI

Bartner LR, McGrath S, Rao S, Hyatt LK, Wittenburg LA. Pharmacokinetics of cannabidiol administered by 3 delivery methods at 2 different dosages to healthy dogs. Can J Vet Res. (2018) 82:178−83. PubMed PMC

Deabold KA, Schwark WS, Wolf L, Wakshlag JJ. Single-dose pharmacokinetics and preliminary safety assessment with use of CBD-rich hemp nutraceutical in healthy dogs and cats. Animals. (2019) 9:832. 10.3390/ani9100832 PubMed DOI PMC

Hartsel JA, Boyar K, Pham A, Silver RJ, Makriyannis A. Cannabis in veterinary medicine: cannabinoid therapies for animals. In: Gupta R, Srivastava A, Lall R, editors. Nutraceuticals in Veterinary Medicine. Cham: Springer; (2019). p. 121–55.

Vaughn D, Kulpa J, Paulionis L. Preliminary investigation of the safety of escalating cannabinoid doses in healthy dogs. Front Vet Sci. (2020) 7:51. 10.3389/fvets.2020.00051 PubMed DOI PMC

Zgair A, Wong JC, Lee JB, Mistry J, Sivak O, Wasan KM, et al. Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines. Am J Transl Res. (2016) 8:3448–59. PubMed PMC

Chan OH, Stewart BH. Physicochemical and drug-delivery considerations for oral drug bioavailability. Drug Discov Today. (1996) 1:461–73. 10.1016/1359-6446(96)10039-8 DOI

Wakshlag JJ, Schwark WS, Deabold KA, Talsma BN, Cital S, Lyubimov A, et al. Pharmacokinetics of cannabidiol, cannabidiolic acid, δ9-tetrahydrocannabinol, tetrahydrocannabinolic acid and related metabolites in canine serum after dosing with three oral forms of hemp extract. Front Vet Sci. (2020) 7:505. 10.3389/fvets.2020.00505 PubMed DOI PMC

Chicoine A, Illing K, Vuong S, Pinto KR, Alcorn J, Cosford K. Pharmacokinetic and safety evaluation of various oral doses of a novel 1:20 THC:CBD cannabis herbal extract in dogs. Front Vet Sci. (2020) 7:583404. 10.3389/fvets.2020.583404 PubMed DOI PMC

Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. (2003) 42:327–60. 10.2165/00003088-200342040-00003 PubMed DOI

MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Intern Med. (2018) 49:12–9. 10.1016/j.ejim.2018.01.004 PubMed DOI

Elsohly MA, Little TL Jr, Hikal A, Harland E, Stanford DF, Walker L. Rectal bioavailability of delta-9-tetrahydrocannabinol from various esters. Pharmacol Biochem Behav. (1991) 40:497–502. 10.1016/0091-3057(91)90353-4 PubMed DOI

Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov. (2007) 6:231–48. 10.1038/nrd2197 PubMed DOI

National Center for Biotechnology Information. PubChem Compound Summary for CID 24699, Glyceryl Monostearate. (2022). Available online at: https://pubchem.ncbi.nlm.nih.gov/compound/Glyceryl-monostearate (accessed March 14, 2022).

Charalambous M, Volk HA, Tipold A, Erath J, Huenerfauth E, Gallucci A, et al. Comparison of intranasal versus intravenous midazolam for management of status epilepticus in dogs: a multi-center randomized parallel group clinical study. J Vet Intern Med. (2019) 33:2709–17. 10.1111/jvim.15627 PubMed DOI PMC

Hjortkjár RK, Bechgaard E, Gizurarson SR, Suzdak C, Mcdonald P, Greenough RJ. Single- and repeated-dose local toxicity in the nasal cavity of rabbits after intranasal administration of different glycols for formulations containing benzodiazepines. J Pharm Pharmacol. (1999) 51:377–83. 10.1211/0022357991772565 PubMed DOI

Rahman M, Lau-Cam CA. Evaluation of the effect of polyethylene glycol 400 on the nasal absorption of nicardipine and verapamil in the rat. Pharmazie. (1999) 54:132–6. PubMed